Landmark Alzheimer's Disease Diagnosis Guideline Released

Strategic Insights -

The Alzheimer's Association has issued a landmark press release, releasing its first clinical practice guideline on the use of blood-based biomarker (BBM) tests for Alzheimer's disease diagnosis. The guideline, presented at the Alzheimer's Association International Conference, provides evidence-based recommendations for healthcare professionals to use blood biomarker tests confidently and consistently. This is a pivotal moment in Alzheimer's care, enabling quicker, more accessible, and more accurate diagnoses.

Key Takeaways:

  • The guideline recommends the use of blood-based biomarker tests with 90% sensitivity and 75% specificity as a triaging test to rule out Alzheimer's pathology.
  • A positive result from a BBM test should be confirmed with another method, such as a cerebral spinal fluid (CSF) or amyloid positron emission tomography (PET) test.
  • BBM tests with 90% sensitivity and specificity can serve as a substitute for PET amyloid imaging or CSF Alzheimer's biomarker testing.
  • The guideline cautions against the overuse or inappropriate use of BBM tests due to variability in diagnostic test accuracy and significant variability in commercially available BBM tests.
  • BBM tests are less costly, more accessible, and more acceptable to patients compared to standard-of-care PET imaging and CSF tests.
  • The guideline emphasizes the importance of a comprehensive clinical evaluation by a healthcare professional and the interpretation of BBM test results within the clinical context.
  • The Alzheimer's Association formed a panel of 11 clinicians, including clinical neurologists, geriatricians, nurse practitioners, and physician assistants, to formulate evidence-based recommendations for using blood-based biomarkers in individuals with objective cognitive impairment.

Statistics:

  • 49 observational studies were reviewed to inform the guideline.
  • 31 BBM tests were evaluated by the panel.
  • 90% sensitivity and 75% specificity are the recommended levels for BBM tests to used as a triaging test.
  • 90% sensitivity and specificity can serve as a substitute for PET amyloid imaging or CSF Alzheimer's biomarker testing.
  • 11 clinicians formed the panel to formulate evidence-based recommendations.
  • The guideline's primary audience includes specialists in neurology, psychiatry, or geriatrics.

Sources:

  • Alzheimer's Association. (2025). Press Release: Alzheimer's Association Releases First Clinical Practice Guideline on Blood-Based Biomarker Tests for Alzheimer's Disease Diagnosis.
  • Alzheimer's & Dementia: The Journal of the Alzheimer's Association. (2025). The use of blood-based biomarker tests in the diagnostic workup of patients with objective cognitive impairment.